Ossiform

Name: Ossiform
Address: Oslogade 1, Odense, 5000, DK
Telephone: +4553600670

Hjem
Danmark
Odense
Ossiform

Kontaktoplysninger, kart og anvisninger, kontaktformular, åbningstider, tjenester, stjerner, fotos, videoer og meddelelser fra Ossiform, Videnskab, teknologi og ingeniørarbejde, Oslogade 1, Odense.

Ossiform® is a British-Danish MedTech company that develops bio-integrative bone substitutes, tailored to improve bone healing outcomes, simplify complex procedures, and reduce complication rates in orthopedics and spine.

27/08/2026

Ossiform is at TechBBQ today!

If you are around, come over for a chat with our CEO, Thea Wulff Olesen and Product Specialist, Pernille Yde Øhlenschlæger Nielsen.

You will find us in the Life Science Invest area 🦴

TechBBQ

29/07/2026

See you at TechBBQ 2026!

Ossiform CEO, Thea Wulff Olesen, and Product Specialist, Pernille Øhlenschlæger, will attend this year’s TechBBQ on August 27 in Bella Center, Copenhagen.

TechBBQ has become one of Europe’s leading startup and innovation events, bringing together founders, investors, researchers, industry leaders, and tech professionals to explore new ideas, build partnerships, and shape the future of technological innovation.

At Ossiform, we are dedicated to improving the lives of people with bone defects with 3D printed, bio-integrative bone substitute solutions. Events like TechBBQ provide an amazing opportunity to connect with other innovators and tech investors to discuss how breakthrough technologies can create real clinical impact.

If you are attending TechBBQ and would like to learn more about Ossiform, we would love to meet with you there.

02/07/2026

We are pleased to share that Ossiform has been invited to present at Lux Research's upcoming Ideathon on Biomedical Materials & Composites, taking place on July 7, 2026 🦴

As a company operating at the intersection of 3D printed biomaterials and tissue engineering, Ossiform is committed to advancing dialogue around emerging materials technologies and their applications in orthopedic care. Events such as the Lux Research Ideathon provide a valuable opportunity to connect with researchers, innovators, and industry leaders to discuss how biomaterials and composites can help shape the next generation of orthopedic solutions.

Our CCO, Monica Wellejus, will represent the company and contribute to discussions alongside leading experts exploring new developments and opportunities within the fields of biomaterials and orthopedics💡

We look forward to contributing to the event and supporting the continued evolution of regenerative and orthopedic technologies.

Learn more about Lux Research: https://luxresearchinc.com/overview/

30/06/2026

📢 Newsletter launch tomorrow, and a sneak peek 👀

The first edition of our quarterly newsletter is released tomorrow, July 1. If you haven’t signed up yet, you can still make it!

We will be sharing Ossiform’s progress over the last quarter, upcoming activities and events, and key priorities in the coming months.

If you want to follow along, subscribe to the newsletter here: https://lnkd.in/eSFRMk42.

25/06/2026

We’re excited to announce that Ossiform has partnered with Imbros as our new distributor for Australia and New Zealand🌏

With over 50 years of experience supplying scientific instruments across Oceania, Imbros has a strong track record of delivering innovative technologies to market, making them an ideal partner to support the distribution of Ossiform’s P3D Scaffolds in the region.

Through this collaboration, we aim to empower more researchers to explore new possibilities in bone research and tissue engineering🦴

We look forward to working with the Imbros team to support the scientific community across Australia and New Zealand.

🔗 Learn more about Imbros: https://imbros.com.au/product/ossiform-p3d-scaffolds/

02/06/2026

How can bone-mimicking scaffolds be used in cancer research? 🦴

While cancer research has come far with the use of traditional 2D cell cultures and various animal models, three-dimensional tumor models – also called tumoroids – are an emerging tool within the field.

Tumoroids have the ability to replicate key features of the tumor micro-environment, which in turn offer a more physiologically relevant disease model that retains the biological characteristics of the primary tumor🧫

Tumoroids are typically derived from patient cancer cells or immortalized cancer cell lines and they can enable:
- Studies of tumor-matrix interactions
- Evaluation of anticancer therapies
- Investigation of metastatic mechanisms

Many solid tumors and cancer types – including breast and prostate cancer – metastasize to our bones. Yet bone metastasis remains one of the most difficult aspects of cancer biology to model in vitro due to the complexity of the tissue.
By providing a mineralized, bone-mimicking microenvironment, the P3D Scaffolds from Ossiform enable researchers to grow 3D tumoroids that accurately replicate the tumor-host tissue interactions in a physiologically relevant setting without the use of animal models🐀

Such bone cancer model makes it possible to:
- Investigate how cancer cells colonize and adapt to bone
- Study metastatic mechanisms in a controlled system
- Screen anticancer therapies with improved translational relevance

As the field moves toward scalable, human-relevant research platforms, tumoroids represent a powerful alternative to traditional 2D cultures and many animal models.

Learn more about how P3D Scaffolds and tumoroids advance bone metastasis research and therapeutic development: https://ossiform.com/how-miniature-tumors-can-be-grown-on-p3d-scaffolds-for-cancer-research/

07/05/2026

We’re excited to share that Ossiform is heading to Tennessee as part of the ABHI US Accelerator 2026!

From 11–15 May, we’ll be in Memphis and Nashville, meeting with senior leaders, innovation teams, and clinicians across leading health systems, including Baptist Memorial Health, Vanderbilt University Medical Center, LifePoint, HCA, and many more🩺

A fantastic opportunity to showcase Ossiform and explore new collaborations in the US market. Looking forward to a great week of conversations💬

30/04/2026

What have we been up to lately?
Short answer: quite a lot.

We are launching a quarterly newsletter to share what we have been working on, our progress across key initiatives, and where we are headed next. Each edition brings highlights from the past quarter and a preview of what is coming.

If you would like a closer look at how Ossiform is evolving, you are very welcome to join.

Subscribe via our website or use the form linked below to follow along 👇

Ossiform news: https://ossiform.com/press-releases-and-news/
Direct link to the sign-up form: https://2fzpgw.share-eu1.hsforms.com/2qMP6Ooe5RPmoUKvvUC9gbA

28/04/2026

From bench to bedside – 3D printing in action.

What began as early validation of Ossiform’s proprietary 3D printing technology eventually led to the launch of our bone-mimicking 3D cell culture systems, the P3D Scaffolds🦴

Before a new technology or medical device can safely enter the market, extensive pre-clinical testing is required to investigate cellular and biological effects. To support this process, Ossiform developed 3D cell culture scaffolds produced using the same technology and material as our medical devices. These scaffolds were used in early in vitro and in vivo studies to demonstrate biological compatibility.

Recognizing a broader need for such systems within the academic bone research community, we made these scaffolds available to researchers around the world under the name P3D Scaffolds.

Since then, we have conducted multiple investigations, refined experimental protocols, generated robust datasets, and delivered thousands of scaffolds, enabling effective, translatable, bone-mimicking experimental models 🔬

The P3D Scaffolds are a classic example of how technology can bridge pre-clinical insights with clinical relevance and ultimately move innovations from bench to bedside.

In this short video clip from the recent online event “Bench to Bedside: Bioprinting Innovations” hosted by Jenny Chen from 3dheals , Ossiform’s CCO, Monica Wellejus, highlights key findings from our in-house investigations using P3D Scaffolds.

24/04/2026

Ossiform is pleased to announce that Gijs Klarenbeek, MD, has joined the company as Clinical- / Medical Affairs Advisor.

In this role, Gijs will support the continued strengthening of Ossiform’s clinical and medical affairs activities as the company prepares for launch and clinical adoption in the United States and initiates the studies to obtain the CE mark.

Gijs will contribute to the successful clinical implementation of Ossiform’s bio-integrative, 3D printed bone substitutes and surgical instrumentation across the U.S. and Europe. His work will focus on ensuring robust evidence generation and dissemination, supporting surgeon training and medical education, collaborating closely with key opinion leaders, CROs, and contributing to post-market regulatory and adoption activities.

Adresse

Oslogade 1
Odense
5000

Telefon

+4553600670

Internet side

https://www.ossiform.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når Ossiform sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.